Evidence map›Paper›PMID 34605595›Full record

ArticleChembiochem : a European journal of chemical biology2021

Systematic Evaluation of Fluorination as Modification for Peptide-Based Fusion Inhibitors against HIV-1 Infection.

Susanne Huhmann, Elisabeth K Nyakatura, Anette Rohrhofer, Johann Moschner, Barbara Schmidt, Jutta Eichler, Christian Roth, Beate Koksch

Open access · hybridAbstract read
In one paragraph

Article in Chembiochem : a European journal of chemical biology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.7field-weighted citation impact, top 34% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 8 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 5 institutions in 2 countries.

Susanne HuhmannFreie Universität Berlin, Department of Biology, Chemistry and Pharmacy, Institute of Chemistry and Biochemistry, Arnimallee 20, 14195, Berlin, Germany.ORCID 0000-0001-5519-3426
Elisabeth K NyakaturaFreie Universität Berlin, Department of Biology, Chemistry and Pharmacy, Institute of Chemistry and Biochemistry, Arnimallee 20, 14195, Berlin, Germany.
Anette RohrhoferInstitute of Clinical Microbiology and Hygiene, Regensburg University Hospital, Franz-Josef-Strauß-Allee 11, 93053, Regensburg, Germany.
Johann MoschnerFreie Universität Berlin, Department of Biology, Chemistry and Pharmacy, Institute of Chemistry and Biochemistry, Arnimallee 20, 14195, Berlin, Germany.
Barbara SchmidtInstitute of Clinical Microbiology and Hygiene, Regensburg University Hospital, Franz-Josef-Strauß-Allee 11, 93053, Regensburg, Germany.ORCID 0000-0003-0059-0349
Jutta EichlerFriedrich-Alexander-Universität Erlangen-Nürnberg, Department Chemie und Pharmazie, Nikolaus-Fiebiger-Str. 10, 91058, Erlangen, Germany.ORCID 0000-0001-6683-9456
Christian RothMax Planck Institute of Colloids and Interfaces, Biomolecular Systems, Arnimallee 22, 14195, Berlin, Germany.ORCID 0000-0001-5806-0987
Beate KokschFreie Universität Berlin, Department of Biology, Chemistry and Pharmacy, Institute of Chemistry and Biochemistry, Arnimallee 20, 14195, Berlin, Germany.ORCID 0000-0002-9747-0740
Freie Universität Berlin · DEUniversity Hospital Regensburg · DEFriedrich-Alexander-Universität Erlangen-Nürnberg · DEMax Planck Institute of Colloids and Interfaces · DETri-Institutional Therapeutics Discovery Institute · US

Funding

DFG 387284271HZB BerlinMax Planck SocietyWyatt Technology Europe GmbH
6 · The paper itself

Abstract

With the emergence of novel viruses, the development of new antivirals is more urgent than ever. A key step in human immunodeficiency virus type 1 (HIV-1) infection is six-helix bundle formation within the envelope protein subunit gp41. Selective disruption of bundle formation by peptides has been shown to be effective; however, these drugs, exemplified by T20, are prone to rapid clearance from the patient. The incorporation of non-natural amino acids is known to improve these pharmacokinetic properties. Here, we evaluate a peptide inhibitor in which a critical Ile residue is replaced by fluorinated analogues. We characterized the influence of the fluorinated analogues on the biophysical properties of the peptide. Furthermore, we show that the fluorinated peptides can block HIV-1 infection of target cells at nanomolar levels. These findings demonstrate that fluorinated amino acids are appropriate tools for the development of novel peptide therapeutics.

Indexed as

Anti-HIV AgentsHalogenationHIV-1HIV Envelope Protein gp41HIV Fusion InhibitorsHIV InfectionsHumansMicrobial Sensitivity TestsPeptidesAnti-HIV Agentsgp41 protein, Human immunodeficiency virus 1HIV Envelope Protein gp41HIV Fusion InhibitorsPeptidesfluorinated amino acidsgp41medicinal chemistryprotein engineeringprotein-protein interactions

Identifiers

PMID34605595
PMCPMC9297971
OpenAlexW3202145646

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.